A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors

As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Aerin, Lee, Shinai, Lee, Sua, Lim, Sojung, Park, Yong-Yea, Song, Eunjung, Kim, Dong-Sik, Kim, Kisu, Lim, Yangmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175222/
https://www.ncbi.nlm.nih.gov/pubmed/32143496
http://dx.doi.org/10.3390/biom10030399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175222/
https://www.ncbi.nlm.nih.gov/pubmed/32143496
http://dx.doi.org/10.3390/biom10030399

Ejemplares similares